M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
Pfizer bowed out of a troubled joint venture with China's Hisun Pharma, which sells branded generic drugs in China.
In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.
Big Pharma expanded in emerging markets by 6.1% last quarter, but GSK and Eli Lilly didn't reap as much growth as their peers
Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.
Sun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a of a host of issues that contributed to a 74% profit slide.
Sun's quarterly U.S. sales dropped 42%, BeiGene offers a public offering of $175 million and the FDA sent a Form 483 to Biocon.
Dr. Reddy's CEO GV Prasad says the generic drugmaker’s top priority is to do what is needed to get its manufacturing up to FDA expectations.
It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
Problems at Lupin’s plant in Goa, India, hit the drugmaker’s latest earnings with a double whammy, undercutting its U.S. sales while raising costs.